Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States.
Sangamo Therapeutics and Pfizer announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.
Cellectis has secured approval from the US Food and Drug Administration (FDA) to launch a phase 1 clinical trial for the evaluation of its gene-edited T-cell product candidate UCARTCS1 as a potential treatment for multiple myeloma (MM).
Roche said that ipatasertib, in combination with Tecentriq (atezolizumab) and chemotherapy, demonstrated promising anti-tumor activity in advanced triple-negative breast cancer in a Phase Ib study.
Silence Therapeutics has filed a clinical trial application (CTA) with the UK Medicines and Healthcare products Regulatory Agency (MHRA), seeking approval to launch a phase Ib trial for the investigational drug, SLN124.
UK-based clinical-stage company Evgen Pharma reported that its phase 2 STEM trial evaluating SFX-01 for the treatment of metastatic breast cancer has met its primary endpoints.
Aimmune Therapeutics said that a phase 3 trial held in Europe that evaluated its lead candidate AR101 for the treatment of peanut allergy, met its primary efficacy endpoint.
Conatus Pharmaceuticals has announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis.
GlaxoSmithKline (GSK) announced that 60% of patients with relapsed / refractory multiple myeloma securing GSK2857916 anti-B-cell maturation antigen (BCMA) antibody-drug conjugate achieved an overall response rate (ORR) in DREAMM-1 study.
Merck KGaA and Pfizer have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (stage III or stage IV).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.